Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia

Cheng Yi Wang, Chia Hung Chen, Chih Yen Tu, Wei Chih Chen, Li Kuo Kuo, Yao Tung Wang, Pin Kuei Fu, Shih Chi Ku, Wen Feng Fang, Chin Ming Chen, Chih Cheng Lai

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Purpose: To compare the clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia (CAP). Patients and methods: We identified patients with severe CAP who received piperacillin-tazobactam based on a nine-center registry database. Furthermore, we classified the patients in three hospitals, which used only branded piperacillin-tazobactam as the study group, and the patients in six other hospitals, which used both branded and generic products as the control group. Results: A total of 472 patients (n = 263 in the study group and n = 209 in the control group) with severe CAP were included. The study group using branded piperacillin-tazobactam had higher odds of clinical cure (adjusted odds ratio [OR] = 3.77, 95 % confidence interval [CI], 1.93–7.37) and lower odds of treatment failure (adjusted OR = 0.28, 95 % CI, 0.13–0.58) than the control group receiving either branded or generic piperacillin-tazobactam. In addition, the study group was associated with higher odds of clinical effectiveness (adjusted OR = 2.95, 95 % CI, 1.46–6.11), less odds of clinical ineffectiveness (adjusted OR = 0.39, 95 % CI, 0.18–0.81), and lower risk of in-hospital mortality (adjusted OR = 0.39, 95 % CI, 0.21–0.73). Conclusion: Based on the findings of the present study using indirect comparison, the clinical effectiveness of generic piperacillin-tazobactam for treating patients with severe CAP might not be as good as that of brand-name products.

Original languageEnglish
Pages (from-to)961-965
Number of pages5
JournalJournal of Infection and Public Health
Volume15
Issue number9
DOIs
Publication statusPublished - Sept 2022

Keywords

  • Brand-name
  • Community-acquired pneumonia
  • Effectiveness
  • Generic name
  • Piperacillin-tazobactam

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia'. Together they form a unique fingerprint.

Cite this